Five stocks stand out heading into Tuesday, October 13, 2026, each carrying a bullish rating change issued on Monday, October 12. Stocks traded normally on October 12 while the bond market closed for Columbus Day. The 10-year Treasury yield reached 5.35% during the week of October 5, its highest level since 2002. Third-quarter earnings season begins on October 13, when JPMorgan Chase and Goldman Sachs report. The September Consumer Price Index follows on October 14, with forecasts calling for a 0.6% monthly rise and a 3.6% annual rate. As of October 12, Kalshi traders priced an 82% chance that the Federal Reserve holds rates at its October 27-28 meeting.
The five ideas below span business software, wireless telecom, biotechnology, solar manufacturing, and insurance brokerage. Editorial notes only, not investment advice.
Salesforce (CRM) – BofA Makes a Double Upgrade
Salesforce was upgraded two notches, from Underperform to Buy, on Monday by BofA analyst Tal Liani, who raised his price target to $285 from $160. Salesforce is the leading provider of customer relationship management software. In our view, its AI agent products and steady cash generation give it a credible path to faster growth, while the valuation remains moderate for a large software company.
Shares traded near $232.08 during Monday's session, up about 1.29%, giving Salesforce a market capitalization near $190 billion. The 52-week range runs from $146.32 to $269.11, the trailing price-to-earnings multiple is 21.20, and the dividend yield is near 1%.
Consensus reads buy, with 24 bullish, nine neutral, and one bearish rating among 34 tracked firms. The average price target of $277.56 implies roughly 20% upside, while the BofA target implies about 23%.
Risks: Citigroup's Tyler Radke holds Neutral at $204, and UBS's Karl Keirstead holds Neutral at $210. Competition from AI-native software vendors, slower seat growth, and the cost of acquisitions all remain factors to monitor.
T-Mobile US (TMUS) – Raymond James Upgrades the Wireless Carrier
T-Mobile was upgraded from Market Perform to Outperform on Monday by Raymond James. T-Mobile is the second-largest U.S. wireless carrier and has led the industry in subscriber growth. In our view, the stock's slide toward its 52-week low has left the valuation more attractive for a business with steady cash flow and a growing broadband segment.
Shares traded near $153.22 during Monday's session, up about 3.12%, giving T-Mobile a market capitalization near $164 billion. The stock sits just above its 52-week low of $147.90 and well below its high of $230.65. The trailing price-to-earnings multiple is 16.03, and the dividend yield is near 3%.
Consensus reads strong buy, with 15 bullish and three neutral ratings among 18 tracked firms. The average price target of $240.67 implies roughly 57% upside, though many targets predate the decline. Scotiabank's Maher Yaghi cut his target to $212 on October 9, implying about 38%.
Risks: Barclays' Kannan Venkateshwar cut his target to $200 from $215 on September 29. Price competition from cable companies and rival carriers, slower subscriber additions, and high spending on network upgrades all remain factors to monitor.
Biogen (BIIB) – JPMorgan Upgrades the Neuroscience Drug Maker
Biogen was upgraded from Neutral to Overweight on Monday by JPMorgan analyst Chris Schott, who raised his price target to $300 from $210. That new target ties the high end of the panel. Biogen develops treatments for multiple sclerosis, Alzheimer's disease, and other neurological conditions. In our view, newer product launches are starting to offset declines in older multiple sclerosis drugs.
Shares traded near $234.21 during Monday's session, up about 3.76%, giving Biogen a market capitalization near $35 billion. The stock sits near its 52-week high of $238.24 and well above its low of $138. The trailing price-to-earnings multiple is 41.51.
Consensus reads buy, with 14 bullish, eight neutral, and one bearish rating among 23 tracked firms. The average price target of $231.43 sits just below the current price, while the JPMorgan target implies roughly 28% upside. UBS's Michael Yee raised his target to $270 on October 9.
Risks: Truist's Srikripa Devarakonda held Hold at $189 in April. Clinical trial results, slow uptake of Alzheimer's treatments, and generic competition all remain factors to monitor.
First Solar (FSLR) – Truist Upgrades the Solar Panel Maker
First Solar was upgraded from Hold to Buy on Monday by Truist analyst Christopher Souther, who raised his price target to $270 from $229. First Solar is the largest U.S.-based solar panel manufacturer. In our view, its domestic production and contracted backlog position it well as power demand from data centers grows.
Shares traded near $180.88 during Monday's session, up about 1.72%, giving First Solar a market capitalization near $19 billion. The stock sits just above its 52-week low of $168.60 and well below its high of $320.95. The trailing price-to-earnings multiple is 11.11.
Consensus reads buy, with 21 bullish, four neutral, and two bearish ratings among 27 tracked firms. The average price target of $261.93 implies roughly 45% upside, and the Truist target implies about 49%.
Risks: Goldman Sachs' Brian Lee cut his target to $272 from $310 on October 8 while holding Buy. Changes to federal clean-energy tax credits, competition from imported panels, and high financing costs for solar projects all remain factors to monitor.
Brown & Brown (BRO) – Two Bullish Calls on the Insurance Broker
Brown & Brown drew two bullish calls on Monday. Keefe, Bruyette & Woods upgraded the stock from Market Perform to Outperform, and TD Cowen initiated coverage at Buy. Brown & Brown is one of the largest U.S. insurance brokers. In our view, the stock's steep decline has priced in much of the slowdown in insurance pricing, leaving a lower valuation for a steady fee-based business.
Shares traded near $63.52 during Monday's session, up about 1.02%, giving Brown & Brown a market capitalization near $21 billion. The 52-week range runs from $53.81 to $95.69, the trailing price-to-earnings multiple is 18.80, and the dividend yield is near 1%.
This is a contrarian call. Consensus reads hold, with three bullish, 11 neutral, and one bearish rating among 15 tracked firms. The average price target of $75.60 implies roughly 19% upside.
Risks: Wells Fargo's Elyse Greenspan held Equal-Weight at $68 on October 12, and Mizuho's Yaron Kinar cut his target to $78 from $83 on October 7. Softer insurance pricing, slower organic growth, and acquisition integration all remain factors to monitor.
Found this helpful? Share it with others.